No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
This article was originally published in The Gray Sheet
Executive Summary
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C
You may also be interested in...
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
Abbott Drops ZoMaxx Stent In Favor Of Xience On Trial Results Slated For TCT
Following a review of its most recent trial data, Abbott has decided to refocus its drug-eluting stent development efforts on its recently acquired Xience V system and drop its in-house ZoMaxx stent program